Event-Driven Stocks

Gain Therapeutics, Inc.

GANXNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue——$55,180$132,640$133,928$28,881
Operating income−$18.7M−$20.4M−$22.3M−$17.8M−$13.8M−$3.5M
Net income−$20.2M−$20.4M−$22.3M−$17.6M−$13.9M−$3.6M
Total assets$22.8M$12.1M$18.6M$24.1M$39.0M$9.6M
Total liabilities$4.3M$4.8M$6.0M$5.2M$4.2M$3.4M
Equity$18.6M$7.3M$12.6M$18.9M$34.8M$6.2M
EPS (diluted)$-0.61$-0.89$-1.71$-1.48$-1.37$-1.33
Shares out.27.8M16.2M11.9M11.9M11.9M3.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−108.6%
Return on assets
−88.4%
Return on capital (ROCE)
−96.1%
Liabilities / assets
18.6%
Debt / equity
0.23×
Book value / share
$0.67
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-7.10distress
Accruals / assets
−7.4%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
44
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 2 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20263.2M7.2-8.2%
Apr 30, 20263.4M6.3+3.3%
Apr 15, 20263.3M5.8+1.5%
Mar 31, 20263.3M4.0+14.2%
Mar 13, 20262.9M3.6-0.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)